Dear Valeant...now forget about......Cephalon. And, refocus on... Bioniche Life Sciences. That's BNC.to for short.
Would be perfect, keeping Canadian funded/ grown in Canada. And, the word spoken at the Fairfield Inn back in November is $20 per share would do it. No time to waste...get your investment bankers out to Belleville asap with a proposal. I'm sure you can even reach a terminating deal with Endo with the money you have.
But be quick! Before Endo tries to put in play their hand.
rg P.S...don't hesitate to call if I can help or feel free to go direct to most on this board.
Now, back to my second and bigger glass of wine. Have a nice evening!
Damian Troise, AP Health Writer, On Monday May 2, 2011, 5:03 pm EDT
NEW YORK (AP) -- Teva Pharmaceutical Industries Ltd. has agreed to buy Cephalon Inc. for $6.8 billion in a deal that would give the world's largest generic drug developer a range of biotechnology drugs aimed at cancer and other conditions.
Teva, based in Israel, said Monday it will pay $81.50 per share cash, marking a 5.8 percent premium to Cephalon's closing price on Friday. The price is a 12 percent premium to the since rejected $73-per-share offer from Valeant Pharmaceuticals International Inc., made March 29. The latest offer represents a 39 percent premium to Cephalon's stock prior to Valeant's unsolicited offer.